drugset / Trial / NCT01360970

Hepatitis A Vaccine in Patients With Immunomodulating Drugs

NCT01360970

Phase 2 Completed 68 enrolled Lars Rombo
NaSingle-groupOpen-labelPrevention

Summary

Hepatitis A vaccine is the most frequently used traveller's vaccine, yet data on its ability to induce protective immunity in immunosuppressed travellers are scarce. The investigators assess the hepatitis A virus (HAV) antibody response in patients with rheumatoid arthritis (RA) treated with Tumor Necrosis Factor (TNF) - inhibitors and/or methotrexate (Mtx).

Timeline

Start
2009-09
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Epaxal Vaccine 0.5 ml Intramuscular
Subject Havrix Vaccine 1 ml Intramuscular

Indications

No indication recorded.